Top

Published in:

01-02-2015 | Original Research Article

Risk of Anaphylaxis with Repeated Courses of Rasburicase: A Research on Adverse Drug Events and Reports (RADAR) Project

Authors: Katherine C. Allen, Amanda H. Champlain, Jonathan A. Cotliar, Steven M. Belknap, Dennis P. West, Jayesh Mehta, Steven M. Trifilio

Published in: Drug Safety | Issue 2/2015

Abstract

Background

Rasburicase, a recombinant urate oxidase, is used to rapidly metabolize uric acid in patients with hyperuricaemia. Rasburicase is an immunogenic therapeutic protein, which has been shown to elicit antibody response in 64 % of healthy volunteers within 1–6 weeks after the initial course, with persistent antibodies for over 1 year. Drug labelling indicates that anaphylaxis rarely occurs (in <1 % of patients) after a single course of therapy with rasburicase, but there are no data available on the incidence of anaphylaxis in patients receiving a subsequent rasburicase course.

Objective

The objective of this study was to determine the incidence of anaphylaxis after multiple treatment courses of rasburicase.

Methods

A retrospective chart review was performed on 97 consecutively treated patients who received repeated courses of rasburicase for hyperuricaemia.

Results

None of the 97 patients who were reviewed experienced anaphylaxis during the first rasburicase course; however, six patients (6.2 %) experienced anaphylaxis during a subsequent rasburicase treatment course (p = 0.03).

Conclusion

Anaphylaxis after a second course of rasburicase appears to occur more frequently than described in the US Food and Drug Administration-approved package insert for initial treatment courses. Given the serious nature of anaphylactic events, caution is advised when administering repeated courses of rasburicase.

Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–54.CrossRefPubMedCentralPubMed

Rasburicase [package insert]. Bridgewater: Sanofi-Aventis US LLC; 2009.

Abu-Alfa AK, Younes A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. Am J Kidney Dis. 2010;55(5 Suppl 3):S1–13.CrossRefPubMed

Chester KA, Baker M, Mayer A. Overcoming the immunologic response to foreign enzymes in cancer therapy. Expert Rev Clin Immunol. 2005;1(4):549–59.CrossRefPubMed

Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant. 2005;20(Suppl 6):63–9.

Bennett CL, Nebeker JR, Yarnold PR, et al. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med. 2007;167(10):1041–9.CrossRefPubMed

Bennett CL, Nebeker JR, Lyons EA, et al. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA. 2005;293(17):2131–40.CrossRefPubMed

Trifilio SM, Pi J, Zook J, et al. Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. Bone Marrow Transplant. 2011;46(6):800–5.CrossRefPubMed

Trifilio S, Gordon L, Singhal S, et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant. 2006;37(11):997–1001.CrossRefPubMed

10.

Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3–11.CrossRefPubMed

11.

Shimada M, Johnson RJ, May WS Jr, et al. A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome. Nephrol Dial Transplant. 2009;24(10):2960–4.CrossRefPubMed

12.

Ejaz AA, Mu W, Kang DH, et al. Could uric acid have a role in acute renal failure? Clin J Am Soc Nephrol. 2007;2(1):16–21.CrossRefPubMed

13.

Dingermann T. Recombinant therapeutic proteins: production platforms and challenges. Biotechnol J. 2008;3(1):90–7.CrossRefPubMed

14.

Pui CH. Rasburicase: a potent uricolytic agent. Pharmacother. 2002;3(4):433–42.

15.

Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant. 2006;21(Suppl5):v9–12.CrossRefPubMed

16.

Rasburicase [package insert]. New York: Sanfoi-Synthelabo Inc; 2002.

Title: Risk of Anaphylaxis with Repeated Courses of Rasburicase: A Research on Adverse Drug Events and Reports (RADAR) Project
Authors: Katherine C. Allen
Amanda H. Champlain
Jonathan A. Cotliar
Steven M. Belknap
Dennis P. West
Jayesh Mehta
Steven M. Trifilio
Publication date: 01-02-2015
Publisher: Springer International Publishing
Published in: Drug Safety / Issue 2/2015
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI: https://doi.org/10.1007/s40264-014-0255-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Risk of Anaphylaxis with Repeated Courses of Rasburicase: A Research on Adverse Drug Events and Reports (RADAR) Project

Abstract

Background

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2015

Consensus Recommendations for Systematic Evaluation of Drug–Drug Interaction Evidence for Clinical Decision Support

Cancer Chemotherapy and Cardiac Arrhythmias: A Review

Safety Surveillance of Traditional Chinese Medicine: Current and Future

Effect of An Educational Intervention to Improve Adverse Drug Reaction Reporting in Physicians: A Cluster Randomized Controlled Trial

Pediatric Drug Safety Signal Detection: A New Drug–Event Reference Set for Performance Testing of Data-Mining Methods and Systems

Treating Severe Malaria in Pregnancy: A Review of the Evidence